(19)
(11) EP 2 082 738 A8

(12) CORRECTED EUROPEAN PATENT APPLICATION
Note: Bibliography reflects the latest situation

(15) Correction information:
Corrected version no 1 (W1 A1)

(48) Corrigendum issued on:
23.06.2010 Bulletin 2010/25

(43) Date of publication:
29.07.2009 Bulletin 2009/31

(21) Application number: 09156851.9

(22) Date of filing: 19.12.2006
(51) International Patent Classification (IPC): 
A61K 31/19(2006.01)
 A61P 11/06(2006.01)
(84) Designated Contracting States:
DE ES GB IE IT TR

(30) Priority: 19.12.2005 US 752253 P

(62) Application number of the earlier application in accordance with Art. 76 EPC:
06845745.6 / 1968564

(71) Applicant: ABBOTT LABORATORIES
Abbott Park IL 60064-3500 (US)

(72) Inventors:
  • Thomas, Debra, L.
    Columbus, OH 43221 (US)
  • Mukerji, Pradip
    Columbus, OH 43230 (US)

(74) Representative: Modiano, Micaela Nadia 
Modiano Josif Pisanty & Staub Ltd Thierschstrasse 11
80538 München
80538 München (DE)

 
Remarks:
This application was filed on 31-03-2009 as a divisional application to the application mentioned under INID code 62.
 


(54) Use of beta-hydroxy-beta-methylbutyrate to treat asthma


(57) Disclosed are methods of treating an individual having asthma wherein the method comprises administering to the individual an amount of β-hydroxy-β-methylbutyrate (HMB) effective to modulate or otherwise cause an increase in the ratio of type (1) to type (2) cytokines, including an increase in the ratio of type (1) to type (2) cytokines without a corresponding increase in type (2) cytokine levels. The methods of the present invention arc based upon the discovery that HMB modulates cytokine production, most typically by increasing type (1) cytokines without a corresponding increase in type (2) cytokines.